Table 2. Characteristics and laboratory data on neutropenic patients with and without viral findings.
| Any virus | No virus | ||||
| Characteristics | (n = 56) | (n = 103) | OR (95%CI)a | ||
| No. of females (%) | 21 | (38) | 44 | (43) | 0.80 (0.41–1.6) |
| Age, [years], median (range) | 62 | (20–86) | 60 | (25–86) | n.s. |
| Underlying disease (%) | |||||
| Acute leukemia/MDS | 19 | (34) | 51 | (50) | 0.52 (0.27–1.0)† |
| Chronic myeloid leukemia | 0 | (0) | 1 | (1) | 0.60 (0.02–15) |
| Chronic lymphocytic leukemia | 6 | (11) | 1 | (1) | 12 (1.4–104)** |
| Non-Hodgkin lymphoma | 25 | (45) | 29 | (28) | 2.1 (1.0–4.1)† |
| Myeloma | 4 | (7) | 16 | (16) | 0.4 (0.13–1.3) |
| Hodgkin's disease | 1 | (2) | 3 | (3) | 0.61 (0.06–6.0) |
| Others | 1 | (2) | 2 | (2) | 0.92 (0.08–10.4) |
| No. of autologous HSCT (%) | 2 | (4) | 27 | (26) | 0.10 (0.02–0.46)*** |
| Latest immunosuppressive treatment (%) | |||||
| Monoclonal antibodiesb | 15 | (27) | 10 | (10) | 3.4 (1.4–8.2)** |
| Antineoplastic chemotherapy | 49 | (88) | 98 | (95) | 0.36 (0.11–1.2) |
| Steroids | 22 | (39) | 19 | (18) | 2.9 (1.4–5.9)** |
| Days from treatment to sampling | 12 | (1–1064) | 13 | (2–632) | n.s. |
| Cell countc [/mm3], median (range) | |||||
| Leukocytes | 200 | (<100–1870) | 400 | (<100–3000) | n.s. |
| Neutrophils | <100 | (<100–500) | <100 | (<100–500) | n.s. |
| Lymphocytes | 127 | (14–18552) | 202 | (2.3–1332) | n.s. |
| CD4+ T cells | 38 | (0.06–769) | 93 | (1.4–606) | * |
| CD8+ T cells | 45 | (1.1–1568) | 51 | (0.14–537) | n.s. |
| B cells | 0.2 | (0.02–15061) | 0.4 | (0.02–439) | n.s |
| NK cells | 11 | (1.0–96) | 16 | (0.32–196) | n.s. |
| Monocytes | 21 | (0.03–495) | 86 | (0.03–1337) | n.s. |
| Prophylactic aciclovir (%) | 21 | (38) | 58 | (56) | 0.47 (0.24–0.91)* |
| Presence of fever | 52 | (93) | 71 | (69) | 5.9 (2.0–18)*** |
| Bacterial infectiond | 15 | (27) | 26 | (25) | 1.1 (0.52–2.3) |
NOTE. Characteristics are presented in number and percentage of each group. Medians are followed by range. OR, odds ratio; CI, confidence interval; MDS, myelodysplastic syndrome; NPA, nasopharyngeal aspirate.
a†
, p≤0.10;
*
, p<0.05;
**
, p<0.01;
***
, p<0.001; ns, not significant.
b
Consisting of rituximab, alemtuzumab, ofatumumab, anti thymoglobulin, or gemtuzumab.
c
Except for the leukocyte and neutrophil count, data on cell count were only available from 34 of the episodes with virus and 72 of the episodes without virus.
d
No bacterial diagnostics were performed on patients without fever but are here assumed to be negative.